Press Release

  • Press Release
  • No Likes

ABVC BioPharma Provides 2023 Pipeline Update
ABVC BioPharma Provides 2023 Pipeline Update 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023 read more
  • Press Release
  • No Likes

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the “Investment”) with Lind Global Fund II read more
  • Press Release
  • No Likes

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its Vitargus® medical device, in Australia, was received from the Australian Therapeutic Goods Administration (TGA) read more
  • Press Release
  • No Likes

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.